Treatment of prostate and renal cancer cells with this new compound downregulates nuclear IGFBP-3, through TGF-β, consequently leading to the phenotypic re-differentiation of prostate cancer cells from EMT to MET and ultimately overcoming therapeutic resistance through lifting anoikis resistance [178, 183]. Here, TGFB1 is linked to prostate cancer.